Relay Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About Relay Therapeutics, Inc.

Relay Therapeutics, Inc. (ticker: RLAY) is a U.S.-listed biotechnology company traded on the NASDAQ in the United States. It belongs to the healthcare/pharma complex, but its investment profile is that of a research-intensive, clinical-stage precision medicine company rather than a diversified pharmaceutical group. Founded in 2016 and headquartered in Cambridge, Massachusetts, Relay was built around a differentiated scientific thesis: protein motion matters, and understanding protein dynamics can unlock better drug design than relying on static structural snapshots alone. That platform approach—combining computational methods with experimental biology—has remained central to the company’s identity since inception. ([ir.relaytx.com](https://ir.relaytx.com/news-releases/news-release-details/third-rock-ventures-launches-relay-therapeutics-57-million?utm_source=openai)) Operationally, Relay focuses primarily on oncology, while also describing a broader ambition in genetic disease. Its business model is based on advancing small-molecule precision medicines designed to hit difficult-to-drug targets. The lead asset is zovegalisib, also known as RLY-2608, an investigational allosteric, isoform-selective PI3Kα inhibitor. The company is developing this asset in hormone receptor-positive, HER2-negative breast cancer with PI3Kα mutations, including in combination with fulvestrant, and has also advanced a triplet strategy involving atirmociclib in metastatic breast cancer. Relay’s pipeline history shows a platform-driven R&D engine rather than reliance on a single program. ([ir.relaytx.com](https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-announces-updated-data-rly-2608-fulvestrant?utm_source=openai)) From a competitive standpoint, Relay operates in a highly crowded and scientifically demanding field: targeted oncology and precision medicine. Its potential edge lies in the quality of its discovery platform, the selectivity and mutation coverage of zovegalisib, and the company’s focus on biologically defined patient subsets. That said, the stock still carries the core risks typical of clinical-stage biotech: uncertain trial readouts, regulatory execution risk, cash burn, and the possibility that later-stage data may fail to replicate earlier signals. Competition is intense across PI3K-pathway therapies, breast cancer combinations, and broader targeted oncology franchises. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1812364/000095017025027756/rlay-20241231.htm?utm_source=openai)) Recent developments have been important for the investment case. In 2025 and 2026, Relay reported updated clinical data for zovegalisib combinations, including efficacy signals that the company says support further development. It also announced U.S. FDA Breakthrough Therapy designation for zovegalisib plus fulvestrant in PIK3CA-mutant, HR+/HER2- advanced breast cancer. Most recently, Relay said data support advancing the zovegalisib plus atirmociclib triplet into Phase 3 development for frontline metastatic breast cancer. For investors, Relay looks like a differentiated, catalyst-driven NASDAQ biotech with a clear lead program, meaningful clinical momentum, and substantial binary risk, all rooted in its U.S. Cambridge-based operating model. ([ir.relaytx.com](https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-announces-zovegalisib-granted-breakthrough/?utm_source=openai))